| 產品編號 | bs-14221R-Cy5 |
| 英文名稱 | Rabbit Anti-DDHD1/Cy5 Conjugated antibody |
| 中文名稱 | Cy5標記的磷脂酶DDHD1抗體 |
| 別 名 | DDHD domain containing 1; DDHD domain containing protein 1; KIAA1705; PA-PLA1; PAPLA1; Phosphatidic acid-preferring phospholipase A1 homolog; Phospholipase DDHD1; Spastic paraplegia 28 (autosomal recessive); SPG28. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 細胞生物 信號轉導 新陳代謝 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | (predicted: Human, Mouse, Rat, Dog, Pig, Cow, Rabbit, Sheep, ) |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 100kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human DDHD1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: Phosphatidic acid is released following cell activation and functions as a second messenger in several signaling pathways. DDHD1 is a lipase that catalyzes degradation of phosphatidic acid and attenuates cell activation. Function: Phospholipase that hydrolyzes phosphatidic acid, including 1,2-dioleoyl-sn-phosphatidic acid. The different isoforms may change the substrate specificity. Subunit: Forms homooligomers and, to a much smaller extent, heterooligomers with DDHD2. Subcellular Location: Cytoplasmic Tissue Specificity: Highly expressed in testis. Also expressed in brain, spleen and lung. Only expressed in cerebellum in fetal brain. DISEASE: Spastic paraplegia 28, autosomal recessive (SPG28) [MIM:609340]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. Some SPG28 patients also have distal sensory impairment. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the PA-PLA1 family. Contains 1 DDHD domain. Database links: Entrez Gene: 80821 Human Entrez Gene: 114874 Mouse Omim: 614603 Human SwissProt: Q8NEL9 Human SwissProt: Q80YA3 Mouse Unigene: 125525 Human Unigene: 121918 Mouse Unigene: 163271 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
